IL226095A - History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them - Google Patents

History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them

Info

Publication number
IL226095A
IL226095A IL226095A IL22609513A IL226095A IL 226095 A IL226095 A IL 226095A IL 226095 A IL226095 A IL 226095A IL 22609513 A IL22609513 A IL 22609513A IL 226095 A IL226095 A IL 226095A
Authority
IL
Israel
Prior art keywords
pyrrolo
pyrazol
pyrimidin
pyridin
medicaments
Prior art date
Application number
IL226095A
Other languages
English (en)
Hebrew (he)
Other versions
IL226095A0 (en
Inventor
Hans-Peter Buchstaller
Margarita Wucherer-Plietker
Timo Heinrich
Original Assignee
Merck Patent Gmbh
Hans-Peter Buchstaller
Margarita Wucherer-Plietker
Timo Heinrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Hans-Peter Buchstaller, Margarita Wucherer-Plietker, Timo Heinrich filed Critical Merck Patent Gmbh
Publication of IL226095A0 publication Critical patent/IL226095A0/en
Publication of IL226095A publication Critical patent/IL226095A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL226095A 2010-11-05 2013-05-01 History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them IL226095A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010050558A DE102010050558A1 (de) 2010-11-05 2010-11-05 1H-Pyrrolo[2,3-b]pyridinderivate
PCT/EP2011/005127 WO2012059172A1 (de) 2010-11-05 2011-10-12 1h-pyrrolo[2,3-b]pyridinderivate

Publications (2)

Publication Number Publication Date
IL226095A0 IL226095A0 (en) 2013-06-27
IL226095A true IL226095A (en) 2016-03-31

Family

ID=44897681

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226095A IL226095A (en) 2010-11-05 2013-05-01 History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them

Country Status (11)

Country Link
US (3) US8664236B2 (enExample)
EP (1) EP2635574B1 (enExample)
JP (1) JP5891234B2 (enExample)
CN (1) CN103180320B (enExample)
AR (1) AR083751A1 (enExample)
AU (1) AU2011325480B2 (enExample)
CA (1) CA2816896C (enExample)
DE (1) DE102010050558A1 (enExample)
ES (1) ES2525172T3 (enExample)
IL (1) IL226095A (enExample)
WO (1) WO2012059172A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
AU2013263420A1 (en) * 2012-05-15 2015-01-22 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic Hsp90
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2017184549A1 (en) * 2016-04-18 2017-10-26 Innov17 Llc Pyrrolopyridine retinoic acid receptor-related orphan receptor modulators and uses thereof
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
WO2022203399A1 (ko) * 2021-03-26 2022-09-29 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
US20100267707A1 (en) * 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate

Also Published As

Publication number Publication date
EP2635574B1 (de) 2014-09-10
CA2816896C (en) 2019-01-08
DE102010050558A1 (de) 2012-05-10
IL226095A0 (en) 2013-06-27
CN103180320A (zh) 2013-06-26
EP2635574A1 (de) 2013-09-11
CN103180320B (zh) 2015-10-07
WO2012059172A1 (de) 2012-05-10
US20140100221A1 (en) 2014-04-10
US8895575B2 (en) 2014-11-25
AU2011325480B2 (en) 2015-03-26
JP5891234B2 (ja) 2016-03-22
US20130231519A1 (en) 2013-09-05
CA2816896A1 (en) 2012-05-10
AR083751A1 (es) 2013-03-20
ES2525172T3 (es) 2014-12-18
AU2011325480A1 (en) 2013-05-02
US8664236B2 (en) 2014-03-04
JP2013541565A (ja) 2013-11-14
US9238651B2 (en) 2016-01-19
US20140371215A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
IL226095A (en) History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HRP20181785T1 (hr) Proces za pripremanje metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata za uporabu kao farmaceutski aktivnog sastojka
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
IL223253B (en) History of 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine and their use in the preparation of drugs against pneumovirina
ZA201503828B (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
LT3001903T (lt) 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
IL223844A (en) History of indolysin, a process for their preparation and medical use
SMT202100448T1 (it) Formulazione di impianto di risperidone e/o paliperidone
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
IL219861A0 (en) Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound
ZA201307511B (en) Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
HK1179251A (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees